VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
NBTX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
NBTXNanobiotix S.A.
$27.45$1.4B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
NBTX logo

Nanobiotix S.A.

NBTX
NASDAQ · Oncology Biotech
$27.45
At close - Nov 17, 4:00 PM EST - USD
Market Cap$1.39B
P/E-49.9x
52W High$57.14
Volume107.03K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Milestone-Dependent Revenue Masks Persistent Cash Burn Risk

Nanobiotix's reported revenue is lumpy and partner-linked, swinging from $32.9M in 2023Q4 to negative $16.5M in 2024Q4 and $5.6M in 2026Q2, which suggests top-line results depend on irregular milestone recognition rather than a stable commercial run-rate.

GrowthMixed
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

NBTX price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

5/12 Beats

EPS beat 5 of last 12 quarters

02

Valuation risk

-306% Peers

P/E is 306% below peer median

03

Market leadership

RS 40 · Lag

Laggard (Underperforming 60% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Dec 29

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
NBTX+24.04%
S&P 500 (^GSPC)+7.21%
1-Year Return
NBTX+25.40%
S&P 500 (^GSPC)+10.03%
3-Year Return
NBTX+348.90%
S&P 500 (^GSPC)+49.51%
5-Year Return
NBTX+192.64%
S&P 500 (^GSPC)+52.76%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$30M+512.3% YoY
Net income FY25
-$24M+64.8% YoY
Free cash flow FY25
-$34M-66.5% YoY
Operating margin FY25
-36.5%-987.7 pts YoY
ROIC (FY25)-
Avg ROIC 5Y-
ROE (FY25)-
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate5/12 (45%)
Revenue Beat Rate4/12 (40%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Sep 29, 2026
-$0.80-64.7%
vs -$0.48
$6M+268.9%
vs $2M
Q2 2026
Mar 31, 2026
-$0.46-250.7%
vs $0.30
$4M-93.2%
vs $52M
Q4 2025
Sep 30, 2025
-$0.13+45.9%
vs -$0.25
$31M+31.2%
vs $24M
Q2 2025
Apr 2, 2025
-$1.01-63.5%
vs -$0.62
$22M-709.2%
vs $4M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·6d ago
Voting Rights and Shares Capital of the Company

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

GlobeNewsWire·Oct 24, 2026
NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma

In 24 heavily pre-treated patients with advanced primary cutaneous melanoma whose cancer had progressed after multiple prior lines of therapy including anti-PD-1 therapy, data continue to show an acceptable safety profile and early signals of efficacy 41.7% (10/24) overall response rate (ORR) per RECIST 1.1, including 4 complete responses 75% (18/24) disease control rate (DCR) 17.8 months median Overall Survival Exploratory analysis in a subset of patients (n=8) identified IL-1β, a cytokine linked to treatment-induced anti-tumor immunity, as the most increased plasma cytokine after treatment Investigators concluded that these preliminary findings warrant further evaluation in randomized clinical trials for patients with primary cutaneous melanoma naïve or refractory to anti-PD-1 Data presented at the 2026 Congress of the European Society for Medical Oncology PARIS and CAMBRIDGE, Mass., Oct. 24, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updated results from patients with anti-PD-1-resistant advanced primary cutaneous melanoma treated in the ongoing Phase 1 Study 1100.

Defense World·Oct 3, 2026
Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Time to Sell?

Nanobiotix S.A. - Sponsored ADR (NASDAQ: NBTX - Get Free Report)'s stock price gapped down before the market opened on Thursday. The stock had previously closed at $31.16, but opened at $29.99. Nanobiotix shares last traded at $29.8790, with a volume of 9,803 shares traded. Wall Street Analysts Forecast Growth Several equities analysts have issued reports

Defense World·Oct 2, 2026
Nanobiotix (NASDAQ:NBTX) Sees Large Volume Increase – Still a Buy?

Nanobiotix S.A. - Sponsored ADR (NASDAQ: NBTX - Get Free Report) saw an uptick in trading volume on Wednesday. 90,160 shares changed hands during trading, an increase of 1% from the previous session's volume of 88,938 shares. The stock last traded at $32.0210 and had previously closed at $31.50. Analysts Set New Price Targets NBTX has

Filtered for Nanobiotix S.A.More Headlines
04

Compare before deciding

Benchmark NBTX against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Nanobiotix S.A. (NBTX)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
NBTX logoNBTXNanobiotix S.A.Current
$27.45$1.39B-49.91512.28%-80.83%——
NVCR logoNVCRNovocure Ltd
$11.14$1.29B-10.698.28%-16.78%-35.81%—
ARAY logoARAYAccuray Incorporated
$2.44$7.32M-0.49-12.34%-4.41%-36.6%—
SENS logoSENSSenseonics Holdings, Inc.
$10.16$424.63M-5.4556.89%-204.19%-186.15%—
ONCO logoONCOOnconetix, Inc.
$3.00$1.08M-0.04-67.7%-7423.86%-557.89%—
CELC logoCELCCelcuity Inc.
$58.01$2.83B-12.49——-1522.54%—

Compare NBTX vs Peers

Nanobiotix S.A. (NBTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NVCR

Most directly comparable listed peer for NBTX.

Scale Benchmark

vs MRK

Larger-name benchmark to compare NBTX against a more recognizable public peer.

Peer Set

Compare Top 5

vs NVCR, ARAY, SENS, ONCO

Get notified when NBTX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

NBTX Frequently Asked Questions

Nanobiotix S.A. (NBTX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Nanobiotix S.A.'s revenue?

Nanobiotix S.A. (NBTX) reported $29.6M in revenue in fiscal year 2025. That is 2079% more than the $1.4M of fiscal year 2011.

How fast is Nanobiotix S.A. growing?

Nanobiotix S.A. (NBTX) grew revenue by 512.3% in fiscal year 2025, compared with the prior fiscal year.

Is NBTX profitable?

No. Nanobiotix S.A. (NBTX) reported a net loss of $24.0M in fiscal year 2025.

Dividend & Returns
What is Nanobiotix S.A.'s free cash flow?

Nanobiotix S.A. (NBTX) had negative free cash flow of $34.0M in fiscal year 2025.

What if you invested $1,000 in NBTX back in 2011?

Total return calculator · dividends reinvested · 15+ years of data

See returns →